Discover
IMMX
Immix Biopharma, Inc.
12.50
2 x 9.05
2 x 16.40
bid
ask
-
0.22
1.73%
2 @ 04:05 AM
12.65 +0.15 (1.20%)
| Ytd | 139.01% | |
| 1y | 498.09% |
12.34
day range
12.84
1.98
52 week range
15.10
| Open | 12.68 | Prev Close | 12.72 | Low | 12.34 | High | 12.84 | Mkt Cap | 894.24M |
| Vol | 4.18M | Avg Vol | 1.76M | EPS | -0.88 | P/E | N/A | Forward P/E | -15.83 |
| Beta | 0.11 | Short Ratio | 6.34 | Inst. Own | 78.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-06 | 50-d Avg | 11.35 | 200-d Avg | 8.88 | 1yr Est | 20.27 |
| Income Statement | |||
| Operating Expenses | 12.46M | ||
| Research and Development Expense | 5.33M | ||
| Selling, General and Administrative Expense | 7.12M | ||
| Operating Income | -12.46M | ||
| Income Tax Expense | 14.32K | ||
| Net Income | -11.56M | ||
| Net Income Common Stock | -11.56M | ||
| Net Income Common Stock (USD) | -11.56M | ||
| Consolidated Income | -11.56M | ||
| Earnings per Basic Share | -0.18 | ||
| Earnings per Basic Share (USD) | -0.18 | ||
| Earnings per Diluted Share | -0.18 | ||
| Earning Before Interest & Taxes (EBIT) | -11.54M | ||
| Earning Before Interest & Taxes (USD) | -11.54M | ||
| Weighted Average Shares | 63.77M | ||
| Weighted Average Shares Diluted | 63.77M | ||
| Balance Sheet | |||
| Cash and Equivalents | 225.49M | ||
| Cash and Equivalents (USD) | 225.49M | ||
| Investments | 8.67M | ||
| Investments Current | 6.62M | ||
| Investments Non-Current | 2.05M | ||
| Current Assets | 233.79M | ||
| Property, Plant & Equipment Net | 3.25M | ||
| Total Assets | 239.11M | ||
| Debt Current | 111.11K | ||
| Total Debt | 1.00M | ||
| Current Liabilities | 9.30M | ||
| Debt Non-Current | 890.64K | ||
| Total Liabilities | 10.19M | ||
| Accumulated Retained Earnings (Deficit) | -126.11M | ||
| Accumulated Other Comprehensive Income | 118.72K | ||
| Shareholders Equity | 228.92M | ||
| Shareholders Equity (USD) | 228.92M | ||
| Assets Non-Current | 5.32M | ||
| Total Debt (USD) | 1.00M | ||
| Liabilities Non-Current | 890.64K | ||
| Trade and Non-Trade Payables | 9.19M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 130.88K | ||
| Net Cash Flow from Financing | 155.28M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 146.24M | ||
| Capital Expenditure | -21.04K | ||
| Issuance (Purchase) of Equity Shares | 155.21M | ||
| Net Cash Flow from Investing | 2.67M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 2.69M | ||
| Net Cash Flow from Operations | -11.74M | ||
| Effect of Exchange Rate Changes on Cash | 24.67K | ||
| Share Based Compensation | 978.14K | ||